Preclinical data demonstrated the efficacy of CD123‐NKCE in cancer intervention, leveraging its binding to NKp46 to enable NK cells to target malignancies effectively while avoiding complications associated with CD64, which impedes ADCC. This evidence concerns the gene FCGR1A and cancer.